{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:01:07Z","timestamp":1792976467103,"version":"4.5.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017510","name":"Mass General Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received \u22652 prior lines of therapy. No significant differences were observed between groups for RAS\/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P &amp;lt; 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver\u2019s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0690","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:45:56Z","timestamp":1769791556000},"page":"340-349","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-6151","authenticated-orcid":false,"given":"Nussara","family":"Pakvisal","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."},{"id":[{"id":"https:\/\/ror.org\/05jd2pj53","id-type":"ROR","asserted-by":"publisher"}],"name":"The King Chulalongkorn Memorial Hospital 2 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, , Chulalongkorn University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-8265","authenticated-orcid":false,"given":"Leontios","family":"Pappas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-1651","authenticated-orcid":false,"given":"Bennett A.","family":"Caughey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-5853","authenticated-orcid":false,"given":"Nora K.","family":"Horick","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-1655","authenticated-orcid":false,"given":"Noelia","family":"Tarazona","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."},{"name":"4Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain."},{"name":"5CIBERONC, Carlos III Health Institute, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-1727","authenticated-orcid":false,"given":"Kruti B.","family":"Vora","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-7093","authenticated-orcid":false,"given":"Ben","family":"Ouyang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."},{"name":"6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4494-4161","authenticated-orcid":false,"given":"Aditya","family":"Pandey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-0629","authenticated-orcid":false,"given":"Bryan L.","family":"Peacker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6628-0321","authenticated-orcid":false,"given":"Joie","family":"Sun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4226-7443","authenticated-orcid":false,"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 3 Mass General Brigham Cancer Center, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-654X","authenticated-orcid":false,"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-673X","authenticated-orcid":false,"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6951-8308","authenticated-orcid":false,"given":"Motaz","family":"Qadan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 7 Division of Surgical Oncology, Department of Surgery, , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-5778","authenticated-orcid":false,"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2475-1939","authenticated-orcid":false,"given":"Bruce","family":"Giantonio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1446-2981","authenticated-orcid":false,"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3540-7217","authenticated-orcid":false,"given":"Elizabeth P.","family":"Walsh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-3600","authenticated-orcid":false,"given":"Jefferey W.","family":"Clark","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-2322","authenticated-orcid":false,"given":"David T.","family":"Ting","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-7841","authenticated-orcid":false,"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04py2rh25","id-type":"ROR","asserted-by":"publisher"}],"name":"Mass General Brigham 1 Division of Hematology\/Oncology, , Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026021722523896100_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026021722523896100_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"2026021722523896100_bib3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021722523896100_bib4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.gastha.2023.09.007","article-title":"Colorectal cancer immunotherapy: state of the art and future directions","volume":"2","author":"Cornista","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"2026021722523896100_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"2026021722523896100_bib6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021722523896100_bib7","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021722523896100_bib8","doi-asserted-by":"crossref","first-page":"1112276","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer","volume":"13","author":"Ros","year":"2023","journal-title":"Front Oncol"},{"key":"2026021722523896100_bib9","first-page":"1","article-title":"Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues","volume":"42","author":"Sahin","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026021722523896100_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"2026021722523896100_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026021722523896100_bib12","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"2026021722523896100_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021722523896100_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"2026021722523896100_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021722523896100_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5005\/jp-journals-10018-1241","article-title":"Hepatic metastasis from colorectal cancer","volume":"7","author":"Valderrama-Trevi\u00f1o","year":"2017","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"2026021722523896100_bib17","first-page":"1771","article-title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer: a literature review","volume":"18","author":"Aruquipa","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"2026021722523896100_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","article-title":"Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis","volume":"7","author":"Harmon","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026021722523896100_bib19","doi-asserted-by":"crossref","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026021722523896100_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for microsatellite-stable metastatic colorectal cancer: can we close the gap between potential and practice?","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"2026021722523896100_bib21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 15","key":"2026021722523896100_bib22","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","article-title":"Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results","volume":"34","author":"Overman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2026021722523896100_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2025.43.4_suppl.23","article-title":"Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM)","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026021722523896100_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026021722523896100_bib25","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021722523896100_bib26","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","article-title":"Liver-mediated adaptive immune tolerance","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Immunol"},{"key":"2026021722523896100_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2026021722523896100_bib28","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026021722523896100_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41575-024-00934-z","article-title":"Mechanisms of metastatic colorectal cancer","volume":"21","author":"Ca\u00f1ellas-Socias","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026021722523896100_bib30","doi-asserted-by":"crossref","first-page":"15168","DOI":"10.18632\/oncotarget.14834","article-title":"Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"2026021722523896100_bib31","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026021722523896100_bib32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"issue":"Suppl 16","key":"2026021722523896100_bib33","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2025.43.16_suppl.3553","article-title":"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti\u2013CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2026021722523896100_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2025.43.4_suppl.193","article-title":"Update of phase 1b\/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced\/metastatic MSS CRC","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2026021722523896100_bib35","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.annonc.2025.05.020","article-title":"8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases","volume":"36","author":"Schlechter","year":"2025","journal-title":"Ann Oncol"},{"key":"2026021722523896100_bib36","author":"Adagene","year":"2025","journal-title":"Adagene announces FDA fast track designation for muzastotug (ADG126)"},{"key":"2026021722523896100_bib37","article-title":"Botensilimab + balstilimab vs best supportive care as therapy in chemo-refractory, unresectable, colorectal adenocarcinoma (BATTMAN)"},{"key":"2026021722523896100_bib38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2016.07.013","article-title":"The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients","volume":"66","author":"Mol","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026021722523896100_bib39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"key":"2026021722523896100_bib40","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/cncr.32782","article-title":"Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"126","author":"Petrillo","year":"2020","journal-title":"Cancer"},{"key":"2026021722523896100_bib41","doi-asserted-by":"crossref","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021722523896100_bib42","doi-asserted-by":"crossref","first-page":"751407","DOI":"10.3389\/fimmu.2021.751407","article-title":"Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"2026021722523896100_bib43","doi-asserted-by":"crossref","first-page":"104342","DOI":"10.1016\/j.critrevonc.2024.104342","article-title":"Tumor mutational burden in colorectal cancer: implications for treatment","volume":"197","author":"Marques","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026021722523896100_bib44","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41598-024-53257-z","article-title":"Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes","volume":"14","author":"Zou","year":"2024","journal-title":"Sci Rep"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0690\/3731958\/crc-25-0690.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/340\/3737935\/crc-25-0690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/340\/3737935\/crc-25-0690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:52:49Z","timestamp":1771386769000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/340\/774539\/Effect-of-Liver-Metastases-on-Survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0690","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8315012","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31360448","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360457","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360454","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360451","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360463","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360460","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31360472","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}